Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,231 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease - COPD Clear all
Terminated No phase listed Observational

Use Of Capnography As Surrogate Measure Of PC02 In Medical Intensive Care Unit (ICU) Patients

NCT00744614
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease
Interventions
Capnography
Procedure
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Oct 9, 2026, 6:31 AM EDT
Completed No phase listed Observational

Validation of PROMIS Banks With COPD Exacerbations

NCT00784342
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Evanston, Illinois • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

NCT05166889
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
36
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 9, 2026, 6:31 AM EDT
Terminated Phase 1 Interventional

Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI

NCT05433961
View directory record Official record
Conditions
COPD
Interventions
MagniXene Hyperpolarized Xenon MRI
Drug
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Asthma Programs for Schools

NCT01625364
View directory record Official record
Conditions
Asthma, Reactive Airway Disease
Interventions
SHARP program, Open Airways for Schools
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
9 Years and older
Enrollment
432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 2 Interventional

Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

NCT00993707
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CTX-100 (formerly ETX-100) (hyaluronic acid)
Drug
Lead sponsor
Turino, Gerard, M.D.
Individual
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 9, 2026, 6:31 AM EDT
Terminated Phase 2 Interventional Results available

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00706914
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Placebo to formoterol fumarate, Once-daily formoterol fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
40
States / cities
Tucson, Arizona • Fullerton, California • Lakewood, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01437540
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
137
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 2 Interventional

High Dose Trial in COPD

NCT00128440
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 84 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
13
States / cities
Lakewood, California • Wheat Ridge, Colorado • Pembroke Farms, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 9, 2026, 6:31 AM EDT
Completed No phase listed Observational

Effect of Nasal CPAP on Cardiopulmonary Exercise Testing in Patients With Overlap Syndrome

NCT01033266
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease
Interventions
CPET
Diagnostic Test
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation

NCT01916577
View directory record Official record
Conditions
COPD, Cystic Fibrosis, Pulmonary Fibrosis
Interventions
Plerixafor mobilization of autologous CD117 stem cells
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 9, 2026, 6:31 AM EDT
Terminated No phase listed Observational

A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease

NCT01268072
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
40 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Baltimore, Maryland • Springfield, Massachusetts • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects

NCT02006537
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2256294
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 4 Interventional Results available

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

NCT01443845
View directory record Official record
Conditions
COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
217
States / cities
Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 9, 2026, 6:31 AM EDT
Terminated No phase listed Observational

A Study of Patients With Chronic Disease

NCT04263727
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF, COPD, Respiratory Disease
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Colorado Springs, Colorado • Clearwater, Florida • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 2 Interventional

Promoting Physical Activity in Chronic Obstructive Pulmonary Disease (COPD) Through New Technology and Health Coaching

NCT01217710
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Physical Activity
Interventions
Activity monitor/smartphone health coaching
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 9, 2026, 6:31 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

NCT06944925
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BBT002, Placebo
Drug
Lead sponsor
Bambusa Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 9, 2026, 6:31 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

A Prospective, Cohort Study of Hyperpolarized 3He MRI in Chronic Obstructive Pulmonary Disease

NCT02734368
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Hyperpolarized Helium-3
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 4 Interventional Results available

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

NCT03081156
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler
Drug
Lead sponsor
William Stringer, md
Other
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 3 Interventional

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

NCT00064402
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions
arformoterol tartrate inhalation solution, Salmeterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
65
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

NCT00891462
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
104
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 9, 2026, 6:31 AM EDT
Completed Phase 4 Interventional

Common Canister Protocol for Inhaler Administration in Mechanically Ventilated Patients

NCT01935388
View directory record Official record
Conditions
Ventilator Associated Pneumonia
Interventions
Common canister
Other
Lead sponsor
Barnes-Jewish Hospital
Other
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 9, 2026, 6:31 AM EDT
Not listed Phase 2 Interventional

Biological Effects of Quercetin in COPD Phase II

NCT06003270
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction
Interventions
Quercetin 1000 mg, Quercetin 500 MG, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 9, 2026, 6:31 AM EDT